Current new challenges in the management of ulcerative colitis

Area of Science:

• Gastroenterology
• Immunology
• Pharmacology

Background:

• Ulcerative colitis (UC) is a chronic gastrointestinal inflammatory disease with incompletely understood multifactorial pathogenesis.
• Current UC management primarily relies on immunosuppressive therapies, including thiopurines, anti-TNF-α antibodies, and calcineurin inhibitors for moderate-to-severe cases.

Purpose of the Study:

• To review and compare the features and efficacy of emerging treatments for ulcerative colitis.
• To provide an overview of novel therapeutic strategies beyond conventional immunosuppression for UC.

Main Methods:

• Comparative review of recently reported ulcerative colitis treatments.
• Analysis of novel immunosuppressants (golimumab, anti-α-4/β-7 integrin antibody, JAK inhibitors) and non-immunosuppressive therapies (fecal microbiota transplantation, Indigo naturalis).

Main Results:

• Newer immunosuppressants like golimumab and Janus kinase inhibitors offer alternative mechanisms for UC treatment.
• Non-immunosuppressive approaches, such as fecal microbiota transplantation and Chinese herbal medicine (Indigo naturalis), present unique therapeutic avenues.

Conclusions:

• The landscape of ulcerative colitis treatment is expanding with novel immunosuppressive and non-immunosuppressive options.
• Understanding the features and efficacy of these diverse treatments is crucial for optimizing patient management in UC.